A new combination drug therapy could help people with inflammatory bowel disease (IBD) for whom other medicines have stopped ...

New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease ...

A review of microscopic colitis, a chronic, intermittent inflammatory bowel disease that predominantly affects older women and typically presents with frequent watery, non-bloody stools.

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

For patients with Crohn's disease or ulcerative colitis who have exhausted other treatment options, a new combination therapy ...

LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...

A drug that has already gained FDA approval for the treatment of ulcerative colitis is also effective in the treatment of Crohn’s, new data suggest. Brothers91/Getty Images Recently, the drug’s ...

Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi Images/GHI/UCG/Universal Images ...

Arthritis is the most common nonintestinal complication for people with ulcerative colitis (UC). These tips can help stave it ...

Treatment failure occurs when an ulcerative colitis medication isn’t helping symptoms. Most important, know that it’s not your fault. Learn what to do next.